Lead Optimization of Small Molecule ENL YEATS Inhibitors to Enable In Vivo Studies: Discovery of TDI-11055

Eleven-nineteen leukemia (ENL) is an epigenetic reader protein that drives oncogenic transcriptional programs in acute myeloid leukemia (AML). AML is one of the deadliest hematopoietic malignancies, with an overall 5-year survival rate of 27%. The epigenetic reader activity of ENL is mediated by its...

Full description

Saved in:
Bibliographic Details
Published in:ACS medicinal chemistry letters 2024-04, Vol.15 (4), p.524-532
Main Authors: Michino, Mayako, Khan, Tanweer A., Miller, Michael W., Fukase, Yoshiyuki, Vendome, Jeremie, Adura, Carolina, Glickman, J. Fraser, Liu, Yiman, Wan, Liling, Allis, C. David, Stamford, Andrew W., Meinke, Peter T., Renzetti, Louis M., Kargman, Stacia, Liverton, Nigel J., Huggins, David J.
Format: Article
Language:English
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Eleven-nineteen leukemia (ENL) is an epigenetic reader protein that drives oncogenic transcriptional programs in acute myeloid leukemia (AML). AML is one of the deadliest hematopoietic malignancies, with an overall 5-year survival rate of 27%. The epigenetic reader activity of ENL is mediated by its YEATS domain that binds to acetyl and crotonyl marks on histone tails and colocalizes with promoters of actively transcribed genes that are essential for leukemia. Prior to the discovery of TDI-11055, existing inhibitors of ENL YEATS showed in vitro potency, but had not shown efficacy in in vivo animal models. During the course of the medicinal chemistry campaign described here, we identified ENL YEATS inhibitor TDI-11055 that has an improved pharmacokinetic profile and is appropriate for in vivo evaluation of the ENL YEATS inhibition mechanism in AML.
ISSN:1948-5875
1948-5875
DOI:10.1021/acsmedchemlett.4c00016